Pilot Study of Flesinoxan, a 5-HTIA Agonist, in Major Depression: Effects on Sleep REM Latency and Body Temperature.

Autor: Ansseau, Marc, Pitchot, William, Moreno, Antonio Gonzalez, Wauthy, Jacques, Papart, Patrick
Předmět:
Zdroj: Human Psychopharmacology: Clinical & Experimental; Jul/Aug93, Vol. 8 Issue 4, p279-283, 5p
Abstrakt: Flesinoxan is a highly potent and selective 5-HTIA full agonist, active in several models of depression. In this pilot open study, flesinoxan (4 mg/d) was administered orally for 4 weeks in 16 major depressive, mostly treatment-resistant inpatients exhibiting a score of at least 19 on the Hamilton depression sale. Weekly ratings included Hamilton depression scale, Montgomery and Asberg depression scale (MADRS). and Clinical Global Impressions (CGI). Results showed considerable improvement in depressive symptomatology, with mean MADRS scores (SD) dropping from 35·7 (10·0) to 13·0 (11·9) and CGl-illness severity from 5·69 (1·14) to 2·73 (1·62) alter 4 weeks of treatment. Moreover. 13 patients were classified as much or very much improved on the CGI-global improvement. The tolerance of flesinoxan was excellent, with only four patients exhibiting side-effects. In contrast to acute studies with SHT1A agonists, flesinoxan induced no significant decrease in daily oral temperature over the 4-week period. In eight melancholic patients, the mean REM latency (SD) of respectively 35·6 (15·9) and 40·2 (l7·9) mm during two baseline nights significantly increased to 5I·9 (20·9) mm during a double-blind challenge night with flesinoxan 1 mg as compared to 42·0 (16·1) mm with placebo, and to respectively 55·6 (29·9) and 55·6 (30·2) mm during the lass two treatment nights. All these findings encourage further developments of flesinoxan as a promising antidepressant. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index